Diplomat Pharmacy, Inc. - FORM 10-Q - EX-10.2

Attached files

file	filename
EX-32.1 - EX-32.1 - Diplomat Pharmacy, Inc.	a15-18043_1ex32d1.htm
XML - IDEA: XBRL DOCUMENT - Diplomat Pharmacy, Inc.	R9999.htm
10-Q - 10-Q - Diplomat Pharmacy, Inc.	a15-18043_110q.htm
EX-32.2 - EX-32.2 - Diplomat Pharmacy, Inc.	a15-18043_1ex32d2.htm
EX-31.1 - EX-31.1 - Diplomat Pharmacy, Inc.	a15-18043_1ex31d1.htm
EX-31.2 - EX-31.2 - Diplomat Pharmacy, Inc.	a15-18043_1ex31d2.htm
EX-10.3 - EX-10.3 - Diplomat Pharmacy, Inc.	a15-18043_1ex10d3.htm
EX-10.4 - EX-10.4 - Diplomat Pharmacy, Inc.	a15-18043_1ex10d4.htm

Exhibit 10.2

August 27, 2015

Diplomat Pharmacy, Inc.,
as Borrower, and the other

Credit Parties

4100 S. Saginaw Street

Flint, Michigan 18507

Attention: Sean Whelan,

Chief Financial Officer

Facsimile: (810) 282-0195

Re: Diplomat Pharmacy, Inc. —
Consent to Sale of Compounding Business

Ladies and Gentlemen:

Reference is made to the Second Amended and Restated Credit Agreement dated as of April 1, 2015 (as amended, the “Credit Agreement”), by and among Diplomat Pharmacy, Inc., a Michigan corporation (“Borrower”), the other Credit Parties party thereto, and General Electric Capital Corporation, a Delaware corporation, in its capacity as agent (in such capacity, “Agent”) for the several financial institutions from time to time party thereto. Capitalized terms used in this letter and not otherwise defined herein shall have the respective meanings given to them in the Credit Agreement.

Borrower, as a portion of its business, is engaged in the business of pharmacy compounding, whereby compounded medications are made based on a practitioner’s prescription in which individual ingredients are mixed together in the exact strength and dosage form required by an individual patient’s specific need (the “Non-Core Specialty Compounding Business”). Borrower has advised Agent and the Lenders that it intends to sell certain assets and rights related solely to the Non-Core Specialty Compounding Business, including patient files, formularies of sterile and non-sterile compounds, marketing materials, telephone numbers and fax numbers (collectively, the “Disposed Assets”), pursuant to an Asset Purchase Agreement (the “Purchase Agreement”) between Restore Partners, LLC, a Florida limited liability company (the “Buyer”) and the Borrower (the “Asset Sale”).

The aggregate consideration for the Purchased Assets is expected to be $18.00 per prescription with respect to “Seller-Generated Accounts” during the two-year period commencing on the closing date of the Asset Sale and such consideration will be paid by Buyer on a quarterly basis (the “Deferred Consideration”), with no consideration paid on the closing date (other than the assumption of certain liabilities by the Buyer). “Seller-Generated Accounts” are sales from (i) Borrower’s existing customers for which patient files are transferred to Buyer or (ii) prescriptions received by Buyer via Borrower’s telephone numbers, fax numbers, websites, etc. that constitute the Disposed Assets.

Pursuant to Section 5.2 of the Credit Agreement, the Borrower, the other Credit Parties and their Subsidiaries may not, directly or indirectly, sell, assign, lease, convey, transfer or otherwise dispose of (whether in one or a series of transactions) any Property or enter into any agreement to do any of the foregoing, except as specifically permitted therein. The Borrower has informed the Agent and the Lenders that the Asset Sale, including the nature and timing of the Deferred Consideration, is not permitted under Section 5.2 of the Credit Agreement, absent consent of the Required Lenders, and has requested that the Agent and Required Lenders consent to the Asset Sale and, to the extent constituting an Investment under Section 5.4 of the Credit Agreement, the Deferred Consideration received from the Asset Sale.

Effective as of the date hereof, upon execution of this letter agreement by the Agent, the Required Lenders and the Credit Parties, and receipt by Agent of a true, correct and complete copy of the Purchase Agreement, in reliance upon the representations and warranties of the Credit Parties set forth in the Credit Agreement and notwithstanding any provisions in the Credit Agreement to the contrary, the Agent and the Lenders party hereto hereby consent to and approve the Asset Sale and, to the extent constituting an Investment under Section 5.4 of the Credit Agreement, the Deferred Consideration received from the Asset Sale.

Except to the extent specifically set forth herein, this letter shall not constitute an amendment or waiver by Agent or any Lender of any provisions of the Credit Agreement or any other Loan Document, and all of the provisions of the Credit Agreement and the other Loan Documents shall remain in full force and effect to the extent in effect prior to the date hereof. This letter may be executed in any number of several counterparts, each of which shall be an original, but all of which shall constitute one and the same letter agreement. Delivery of an executed counterpart of a signature page to this letter by facsimile or electronic transmission shall be effective as delivery of a manually executed counterpart thereof. This letter shall be governed by, and construed and enforced in accordance with, the laws of the State of New York applicable to contracts made and performed in such state, without regard to the principles thereof regarding conflict of laws.

[signature pages follow]

	GENERAL ELECTRIC CAPITAL CORPORATION, as Agent, Swingline Lender and as a Lender


	By:	/s/ Karen M. Dahlquist
	Name:	Karen M. Dahlquist
	Title:	Duly Authorized Signatory